Skip to main content

Shattuck Labs, Inc.

corporate_fare Company Profile

Shattuck Labs, Inc.

STTK·NASDAQ·Life Sciences·CIK 0001680367

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases. The company leverages its expertise in protein engineering and tumor necrosis factor (TNF) receptor therapeutics. Its lead program, SL-325, is a high-affinity DR3 blocking monoclonal antibody. SL-325 is designed to more completely block the DR3/TL1A pathway compared to TL1A blocking antibodies. DR3 is the only known receptor for tumor necrosis factor like ligand 1A (TL1A), and TL1A is the only known signaling ligand for DR3, signaling through no other receptors. Preclinical studies showed SL-325 blocked TL1A binding to DR3 more effectively than sequence equivalents of leading TL1A blocking antibodies. The company is currently conducting a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 clinical trial for SL-325 in healthy volunteers, which is expected to be completed in the second quarter of 2026. A randomized, placebo-controlled Phase 2 clinical trial evaluating SL-325 in patients with Crohn's Disease (CD) is expected to begin in the third quarter of 2026.

Shattuck Labs, Inc. (NASDAQ:STTK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for STTK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for STTK spans 8-K, 10-Q, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • Shattuck Q3 Loss Widens to $25.2M as SL-325 Phase 2b Crohn's Trial Begins
  • Shattuck Q3 Loss Widens to $25.2M as R&D Spending Nearly Triples
  • Shattuck Labs Expands SL-325 Into Phase 2 Hidradenitis Suppurativa Trial, Adds Clinical Development SVP
  • Shattuck Labs Q2 2026: Cash Runway into 2029, Phase 2b Crohn's Trial Set for Q3 Launch
  • Shattuck Labs Q2 2026: Cash Runway Extended into 2029, Phase 2b Crohn's Trial to Start in Q3

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1M
Net Income
-$48.81M
Diluted EPS
-$0.70
Op. Cash Flow
-$39.88M
Free Cash Flow
-$39.95M
Operating Income
-$51.51M
Cash & Equivalents
$54.19M
Debt / Equity
0.00×
Net Margin
-48.81×
Shares Outstanding
63.28M sh
Source: 10-K · filed 2026-03-05 · accession 0001628280-26-014989

Short Interest & Short Volume

11.97 days to cover

FINRA reported short interest of 10,745,702 shares in STTK as of the October 30, 2026 settlement, a 2.9% increase from the prior period — about 12.0 days to cover at its recent average daily volume. On November 20, 2026, 53.9% of STTK volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,745,702 shares as of October 30, 2026
Change vs prior period▲ 2.9%
Days to cover11.97 at avg daily volume of 898,075
Daily short volume (FINRA facilities)53.9% of 273,845 shares on November 20, 2026
5-day average short volume48.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for STTK, detected from its recent SEC filings · based on capital-structure filings through 2026-06-11.

1 recent capital raise

Public Offering Finalized · Pricing Details

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$4.47 +0.22% today
52-week range · as of 2026-11-05 $1.72 – $8.33
Market cap
$454.22M
Volume
1M (1.0× avg)
3-mo avg 1M
Live data · 2026-11-22 03:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed STTK - Latest Insights

STTK
Nov 05, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.47 info
Change: -$1.03 (-19%) info
Market Cap: $454.218M info
STTK
Nov 05, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.47 info
Change: -$1.03 (-19%) info
Market Cap: $454.218M info
STTK
Oct 01, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.79
Real-time Price: $4.47 info
Change: -$2.32 (-34%) info
Market Cap: $454.218M info
STTK
Aug 11, 2026, 6:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.47 info
Change: -$2.53 (-36%) info
Market Cap: $454.218M info
STTK
Aug 11, 2026, 6:57 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.47 info
Change: -$2.53 (-36%) info
Market Cap: $454.218M info
STTK
Aug 11, 2026, 6:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.47 info
Change: -$2.53 (-36%) info
Market Cap: $454.218M info
STTK
Jul 17, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $7.09
Real-time Price: $4.47 info
Change: -$2.62 (-37%) info
Market Cap: $454.218M info
STTK
Jun 15, 2026, 6:13 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $4.68
Real-time Price: $4.47 info
Change: -$0.210 (-4%) info
Market Cap: $454.218M info
STTK
Jun 15, 2026, 6:12 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $4.68
Real-time Price: $4.47 info
Change: -$0.210 (-4%) info
Market Cap: $454.218M info
STTK
Jun 15, 2026, 6:10 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.72
Real-time Price: $4.47 info
Change: -$0.250 (-5%) info
Market Cap: $454.218M info
STTK
Jun 11, 2026, 9:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $4.40
Real-time Price: $4.47 info
Change: +$0.070 (+2%) info
Market Cap: $454.218M info
STTK
Jun 11, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $4.47 info
Change: +$0.305 (+7%) info
Market Cap: $454.218M info
STTK
Jun 11, 2026, 6:01 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $4.47 info
Change: +$0.310 (+7%) info
Market Cap: $454.218M info
STTK
Jun 10, 2026, 12:22 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $4.47 info
Change: +$0.300 (+7%) info
Market Cap: $454.218M info
STTK
Jun 09, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $4.15
Real-time Price: $4.47 info
Change: +$0.320 (+8%) info
Market Cap: $454.218M info
STTK
Jun 09, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.07
Real-time Price: $4.47 info
Change: +$0.3982 (+10%) info
Market Cap: $454.218M info
STTK
Jun 09, 2026, 4:18 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $4.47 info
Change: +$0.4699 (+12%) info
Market Cap: $454.218M info
STTK
Jun 09, 2026, 8:02 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.95
Real-time Price: $4.47 info
Change: +$0.520 (+13%) info
Market Cap: $454.218M info
STTK
Jun 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.76
Real-time Price: $4.47 info
Change: -$0.290 (-6%) info
Market Cap: $454.218M info
STTK
May 07, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.48
Real-time Price: $4.47 info
Change: -$2.01 (-31%) info
Market Cap: $454.218M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets